Phase II Study of Oral PRednisone 5 mg Bid Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of Vascular Endothelial Growth Factor Receptor-tyrosine Kinase Inhibitors
Phase of Trial: Phase II
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Everolimus (Primary) ; Prednisone
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Acronyms PREV
- 12 Jan 2018 Status changed from recruiting to discontinued.
- 30 Dec 2015 According to ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.
- 02 Jul 2015 New trial record